ATR-002: Transcriptome Data on MEK1/2 Inhibitor Effects in SARS-CoV-2 Infection

Gene expression data from a transcriptome analysis of SARS-CoV-2-infected Calu-3 cells treated with or without the MEK1/2 inhibitor ATR-002. The dataset was created by Franziska Rodner and last updated on 2026-05-29. It includes measurements of immune regulatory genes such as CXCL10, CCL5, MX1, OASL, EGR1, IFNL1, and NLRP1.

Use Cases

• Identify differentially expressed immune regulatory genes based on transcriptome analysis of infected vs. treated cells.
• Study the modulation of innate immune-response-related genes like cytokines and ISGs mentioned in the description.
• Investigate the link between Raf/MEK/ERK signaling and specific candidate genes (EGR1, IFNL1, NLRP1) in the context of SARS-CoV-2.
• Analyze the anti-inflammatory effects of MEK1/2 inhibition on gene expression patterns described in the results.

Strengths

• Dataset is focused on a specific, clinically relevant host-targeting therapy (ATR-002) for COVID-19.
• Identifies specific candidate genes (EGR1, IFNL1, NLRP1) linked to MEK1/2 inhibition and innate immunity.
• Data is shared under a permissive CC-BY-4.0 license for reuse.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small (400.7 KB), indicating a limited experimental scope.

Provenance

Source

figshare, author Franziska Rodner.

Collection Method

Transcriptome analysis of SARS-CoV-2-infected Calu-3 cells with/without ATR-002 treatment.

Freshness

Last updated 2026-05-29 06:20:23; freshness should be verified.